Publications

Prostate Cancer after Initial High-Grade Prostatic Intraepithelial Neoplasia and Benign Prostate Biopsy

Can J Urol. 2015 Dec;22(6):8056-62.

Patel P, Nayak JG, Biljetina Z, Donnelly B, Trpkov K.

Abstract

INTRODUCTION:

Limited data exist on long term pathological outcomes in patients with initial prostate biopsies showing either high-grade intraepithelial neoplasia (HGPIN) or benign findings, who are subsequently diagnosed with prostate cancer.

MATERIALS AND METHODS:

Preoperative characteristics of patients showing either HGPIN or benign initial prostate biopsies were investigated and compared in patients with and without a subsequent diagnosis of prostate cancer. We also compared the biopsy and prostatectomy findings in patients with prostate cancer in both groups.

RESULTS:

We evaluated 161 and 85 patients with initial HGPIN and benign prostate biopsies, respectively, who underwent a subsequent biopsy. After a median follow up of 11 years, prostate cancer was detected in 26.7% patients after HGPIN and in 22.3% patients after initial benign biopsy. Ninety-eight percent of positive biopsies after initial HGPIN demonstrated either Gleason score (GS) 3 + 3 (86%) or GS 3 + 4 (12%). In the benign group, 100% of patients demonstrated prostate cancer on biopsy with either GS 3 + 3 (58%) or GS 3 + 4 (42%). Of 35 patients who underwent prostatectomy (22 after initial HGPIN biopsy and 13 after initial benign biopsy), all had node negative, organ-confined disease; 86% and 54% patients had GS6 disease, with = 5% tumor volume found in 91% and 62% of the HGPIN and benign group, respectively.

CONCLUSIONS:

Patients with initial HGPIN or benign biopsies preceding a diagnosis of prostate cancer usually show favourable pathology on positive biopsy and prostatectomy, most commonly exhibiting low volume and low grade disease. These findings may help clinicians risk-stratify patients who may benefit from conservative management options.

PubMed

goes to…APCaRI member Russ Greiner

Image of DREAM challenge winners, Russ Greiner pictured on far left.

Dr. Russ Greiner, Canada CIFAR AI Chair, Fellow-in-Residence at Amii, University of Alberta Professor, and APCaRI member, received the CAIAC Lifetime Achievement Award announced at the Canadian AI Conference on May 27, 2021. This the highest honour bestowed by CAIAC, given in recognition to researchers who have distinguished themselves through outstanding research excellence in AI during the course of their academic career. APCaRI congratulates Russ Greiner for his well-deserved CAIAC Lifetime Achievement Award!

“Using machine learning techniques to produce effective, evidence-based personalized treatment”

The main foci of Russ Greiner’s current work are (1) bioinformatics and medical informatics; (2) learning and using effective probabilistic models and (3) formal foundations of learnability. He has published over 200 refereed papers and patents, most in the areas of machine learning and knowledge representation, including 4 that have been awarded Best Paper prizes.

One of these four papers was an entry into an international machine learning competition hosted by DREAM, an open-science effort dedicated to improving health and health care through crowdsourcing problem-solving. DREAM’s challenge was to develop an algorithm to predict which prostate cancer patients would respond to certain treatments and which would follow the medication regimen. The algorithm could be used by clinicians to help chose the best treatment plans for the patient.

Greiner and a team of students tied for the top place in the competition against over 50 teams from around the world. Then the winners collaborated to create an even better solution to the problem!

 

 

 

 

 

 

- Perrin Beatty